Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study
A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.
Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study
A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.
Progress
52% Bias Score
Diabetes Drugs Linked to Reduced Risk of Mental Health Issues
A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...
Diabetes Drugs Linked to Reduced Risk of Mental Health Issues
A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...
Progress
24% Bias Score
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
Progress
36% Bias Score
FDA Approves First Prescription Drug for Obstructive Sleep Apnea
The FDA approved Zepbound, a GLP-1 receptor agonist, as the first prescription drug for moderate-to-severe obstructive sleep apnea in obese patients; clinical trials showed significant improvements in breathing disruptions and weight loss (18-20%), potentially impacting the 30 million Americans with...
FDA Approves First Prescription Drug for Obstructive Sleep Apnea
The FDA approved Zepbound, a GLP-1 receptor agonist, as the first prescription drug for moderate-to-severe obstructive sleep apnea in obese patients; clinical trials showed significant improvements in breathing disruptions and weight loss (18-20%), potentially impacting the 30 million Americans with...
Progress
44% Bias Score
GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions
A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...
GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions
A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...
Progress
44% Bias Score
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes revealed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues, including cardiovascular problems and infections, but increased risks of gastrointestinal issues and low blood pressure.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes revealed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues, including cardiovascular problems and infections, but increased risks of gastrointestinal issues and low blood pressure.
Progress
40% Bias Score
Weight-Loss Injections: Large Study Shows Significant Health Benefits, Rare Risks
A study of nearly two million veterans with type-2 diabetes found that GLP-1 receptor agonists (like Ozempic and Wegovy) significantly reduced risks of heart disease, stroke, neurodegenerative diseases, and mental health issues, despite some rare but serious side effects like pancreatitis and kidney...
Weight-Loss Injections: Large Study Shows Significant Health Benefits, Rare Risks
A study of nearly two million veterans with type-2 diabetes found that GLP-1 receptor agonists (like Ozempic and Wegovy) significantly reduced risks of heart disease, stroke, neurodegenerative diseases, and mental health issues, despite some rare but serious side effects like pancreatitis and kidney...
Progress
40% Bias Score
Weight-Loss Drugs: Successes and Side Effects
This article examines the experiences of three individuals who used GLP-1 receptor agonist medications for weight loss, highlighting both the positive and negative aspects of these drugs.
Weight-Loss Drugs: Successes and Side Effects
This article examines the experiences of three individuals who used GLP-1 receptor agonist medications for weight loss, highlighting both the positive and negative aspects of these drugs.
Progress
24% Bias Score